Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 04-03-2022 | Prostate Cancer | Original Article

Matched-pair analysis of [¹⁷⁷Lu]Lu-PSMA I&T and [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Authors: Philipp E. Hartrampf, Franz-Xaver Weinzierl, Andreas K. Buck, Steven P. Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert Kübler, Andreas Schirbel, Markus Essler, Ralph A. Bundschuh, Rudolf A. Werner

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2022

Abstract

Background

Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT.

Materials and methods

A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [¹⁷⁷Lu]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [¹⁷⁷Lu]Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared.

Results

Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for [¹⁷⁷Lu]Lu-PSMA I&T and five (9.1%) for [¹⁷⁷Lu]Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for [¹⁷⁷Lu]Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with [¹⁷⁷Lu]Lu-PSMA I&T did not differ significantly when compared to patients treated with [¹⁷⁷Lu]Lu-PSMA-617 (median OS, 13 months; P = 0.89).

Conclusion

In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48. https://doi.org/10.1056/NEJMoa1209096.CrossRefPubMed

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoa1405095.CrossRefPubMedPubMedCentral

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. https://doi.org/10.1056/NEJMoa040720.CrossRefPubMed

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26:242–5. https://doi.org/10.1200/jco.2007.12.4008.CrossRef

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376:1147–54. https://doi.org/10.1016/s0140-6736(10)61389-x.CrossRef

Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80:82–94. https://doi.org/10.1016/j.eururo.2021.03.004.CrossRefPubMedPubMedCentral

Calais J, Gafita A, Eiber MR, Armstrong WR, Gartmann J, Thin P, et al. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.261982.CrossRefPubMedPubMedCentral

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33. https://doi.org/10.1016/s1470-2045(18)30198-0.CrossRefPubMed

10.

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase ii prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857–65. https://doi.org/10.2967/jnumed.119.236414.CrossRefPubMedPubMedCentral

11.

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet (London, England). 2021;397:797–804. https://doi.org/10.1016/s0140-6736(21)00237-3.CrossRef

12.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103. https://doi.org/10.1056/NEJMoa2107322.CrossRefPubMedPubMedCentral

13.

Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made dota-conjugated psma inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20. https://doi.org/10.2967/jnumed.114.147413.CrossRefPubMed

14.

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550.CrossRefPubMed

15.

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Mueller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262713.CrossRefPubMedPubMedCentral

16.

Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339–50. https://doi.org/10.1007/s00259-020-05057-6.CrossRefPubMed

17.

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:479–505. https://doi.org/10.6004/jnccn.2019.0023.CrossRefPubMed

18.

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kurpig S, Feldmann G, et al. Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1073–80. https://doi.org/10.1007/s00259-018-4222-x.CrossRefPubMed

19.

Hartrampf PE, Weinzierl F-X, Serfling SE, Pomper MG, Rowe SP, Higuchi T, et al. Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T. Cancers. 2022.

20.

Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; 2017

21.

Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113–22. https://doi.org/10.1007/s00259-020-04797-9.CrossRefPubMed

22.

Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Salvage radiopeptide therapy of advanced castrate-resistant prostate cancer with lutetium-177-labeled prostate-specific membrane antigen: efficacy and safety in routine practice. Cancer Biother Radiopharm. 2018;33:274–81. https://doi.org/10.1089/cbr.2017.2403.CrossRefPubMed

23.

Prive BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, de Groot M, et al. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer. 2020;20:884. https://doi.org/10.1186/s12885-020-07386-z.CrossRefPubMedPubMedCentral

24.

Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1473–9. https://doi.org/10.1007/s00259-017-3681-9.CrossRefPubMed

25.

Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920–6. https://doi.org/10.1016/j.eururo.2018.11.016.CrossRefPubMed

Title: Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Authors: Philipp E. Hartrampf
Franz-Xaver Weinzierl
Andreas K. Buck
Steven P. Rowe
Takahiro Higuchi
Anna Katharina Seitz
Hubert Kübler
Andreas Schirbel
Markus Essler
Ralph A. Bundschuh
Rudolf A. Werner
Publication date: 04-03-2022
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05744-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Matched-pair analysis of [¹⁷⁷Lu]Lu-PSMA I&T and [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Abstract

Background

Materials and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2022

Correction to: First‑in‑human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F‑T‑401

Asinus in Tegulis—basing stark warning messages on insufficient methodology

Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients

The integrated nuclear medicine and radiology residency program in the Netherlands: strengths and potential areas for improvement according to nuclear medicine physicians and radiologists

Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience

Discrepancy between [18F]-FES and [18F]-FDG PET/CT in ER-positive breast cancer with oesophageal metastasis